by Ana Paula Leopercio  , Christini Emori  , Elisabete Calore Neiva  , Ana Lucia Silva Souza  , Ana Cristina Amaral  , Gustavo Almeida Vieira  , Raimundo Araujo Gama  , Jose Osmar Medina-Pestana  and Maria Lúcia Ferraz

Received: 22 June 2022;  Published: 26 October 2022;  doi: 10.21926/obm.transplant.2204168

Hepatitis B virus (HBV) infection is frequent among patients with chronic kidney disease (CKD). HBV reactivation after kidney transplant (KT) is more common in patients with HBsAg+; however, it can also occur in previously infected individuals, particularly those with HBsAg negative and total antiHBc positive (HBsAg-/antiHBcT+). However, reactivation in this population has scarce and conflicting data. This study aimed to assess the reactivation risk in KT recipients with previous HBV infection (antiHBcT+). A retros [...]

by OBM Transplantation Editorial Office

Received: 09 October 2022;  Published: 17 October 2022;  doi: 10.21926/obm.transplant.2204167

by Nicholas J. Geraghty  , Amal Elhage  , Peter Cuthbertson  , Debbie Watson  and Ronald Sluyter

Received: 06 June 2022;  Published: 06 September 2022;  doi: 10.21926/obm.transplant.2203166

Allogeneic hematopoietic stem cell transplantation is a curative therapy for hematological malignancies, but its efficacy is limited by graft-versus-host disease (GVHD). This life-threatening disorder develops when donor (graft) immune cells cause inflammatory damage to recipient (host) tissues. The immune cell receptor channel P2X7 and its ligand adenosine 5’-triphosphate (ATP) have been implicated in GVHD pathogenesis. Therefore, this signaling axis represents a potential therapeutic target. This study aime [...]

by Kurumi Taniguchi  , Haruka Sawamura  , Yuka Ikeda  , Ai Tsuji  and Satoru Matsuda

Received: 02 May 2022;  Published: 30 August 2022;  doi: 10.21926/obm.transplant.2203165

Hematopoietic stem cell transplantation (HSCT) is a standard form of cellular therapy for patients suffering from malignant hematological diseases. However, graft-versus-host disease (GVHD) is a very serious complication and a major cause of morbidity and mortality after allogeneic HSCT. Calcineurin inhibitors, such as cyclosporine, are widely used to enhance the survival of patients who have undergone HSCT. Unfortunately, both GVHD and cyclosporine occasionally cause nephropathy. Several studies have shown that th [...]

by Ginevra G Adamo  , Sergio D'Angelo  , Angeli Christy Yu  , Marco Pellegrini  , Federico Bernabei  , Vincenzo Scorcia  and Giuseppe Giannaccare

Received: 17 June 2022;  Published: 02 August 2022;  doi: 10.21926/obm.transplant.2203164

Graft-versus-host disease (GVHD) is a serious complication that may occur in patients receiving allogeneic hematopoietic stem cell transplant (HSCT). GVHD occurs because of the immunological reaction between the donor’s T cells and the recipient’s antigens; GVHD may develop in different tissues, including the eye. Corneal perforation is an uncommon but vision-threatening manifestation of GVHD. We reported the case of a 65-year-old male patient who developed corneal perforation sequentially in both eyes 3 years afte [...]

by Ibrahim El-Serafi  , Sandra Oerther  , Ying Zhao  and Moustapha Hassan

Received: 08 July 2022;  Published: 27 July 2022;  doi: 10.21926/obm.transplant.2203163

Cytochrome P450 2J2 (CYP2J2) is one of the recently discovered enzymes that is involved in the metabolism of several drugs. It is mainly an extrahepatic enzyme which can, to some extent, explain some the drugs’ side effects such as cyclophosphamide (Cy). Cyclophosphamide is an alkylating agent that is commonly used in conditioning prior to stem cell transplantation. It is a prodrug that is bio-activated by several CYPs including CYP2J2. Cy is known to have several side effects and its extrahepatic activation by CYP [...]

by Maïté Van Hentenryck  , Zhanzhuo Li  , Philip M. Murphy  and Agnieszka Czechowicz

Received: 24 November 2021;  Published: 08 July 2022;  doi: 10.21926/obm.transplant.2203162

The ability to successfully transplant cells and organs from a donor into an immunologically disparate recipient is one of the greatest treatment advances in the history of medicine. Nevertheless, acute and chronic rejection, graft versus host disease, and the inability to identify suitable donors continue to be challenges and limit broader application of cell and organ transplantation to the many patients that could benefit. Immunosuppression before and after allogeneic transplant has been found to dramatically im [...]

by OBM Transplantation Editorial Office

Received: 01 July 2022;  Published: 03 July 2022;  doi: 10.21926/obm.transplant.2203161

by Qiqi Yu  , Kran Suknuntha  , Weixiong Zhong  , Daniel R. Matson  , Aaron S. Hess  and William N. Rose

Received: 13 February 2022;  Published: 02 June 2022;  doi: 10.21926/obm.transplant.2202160

We report a case of thrombotic microangiopathy (TMA) diagnosed in the kidney allograft of a 59-year-old woman who had developed plasmacytoma type monomorphic posttransplant lymphoproliferative disorder (PTLD) 30 years after a simultaneous pancreas and kidney transplant. This report demonstrates a rare etiology of TMA in a kidney allograft occurring in association with PTLD-associated monoclonal gammopathy. The main teaching points are: 1) PTLD may be considered in the work-up of a new TMA in the immunosuppressed po [...]

by OBM Transplantation Editorial Office

Received: 16 May 2022;  Published: 18 May 2022;  doi: 10.21926/obm.transplant.2202159

InterviewAn Interview with Prof. Peter SchemmerOBM Transplantation Editorial OfficeLIDSEN Publishing Inc., 2000 Auburn Drive, One Chagrin Highlands, Suite 200, Beachwood, OH, USA; E-Mail: transplantation@lidsen.com OBM Transplantation2022, volume 6, issue 2doi:10.21926/obm.transplant.2202159Received: May 16, 2022Accepted: May 17, 2022Published: May 18, 2022